Presbia PLC (NASDAQ:LENS) was upgraded by research analysts at Jefferies Group from a “market perform” rating to a “market outperform” rating in a report issued on Tuesday.

Other equities research analysts have also recently issued reports about the company. Rodman & Renshaw set a $14.00 price target on Presbia PLC and gave the company a “buy” rating in a report on Thursday, July 21st. Zacks Investment Research raised Presbia PLC from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a report on Tuesday, June 28th. Finally, TheStreet raised Presbia PLC from a “sell” rating to a “hold” rating in a report on Monday, July 25th.

Shares of Presbia PLC (NASDAQ:LENS) opened at 4.50 on Tuesday. The stock’s market capitalization is $60.02 million. The company’s 50-day moving average price is $4.44 and its 200 day moving average price is $4.54. Presbia PLC has a one year low of $2.94 and a one year high of $6.89.

Presbia PLC Company Profile

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.

5 Day Chart for NASDAQ:LENS

Receive News & Stock Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related stocks with our FREE daily email newsletter.